



DT13 Rec'd PCT/PTO 12 MAY 2003

PCT

PATENT
ST98008A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): CIOLINA, ET AL. EXAMINER : SITA, P.
SERIAL NO. : 09/646,399 ART UNIT : 1636
FILED : NOVEMBER 1, 2000
FOR : NUCLEIC ACID TRANSFER VECTORS, COMPOSITIONS
CONTAINING SAME AND USES

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service via FIRST CLASS mail in an envelope addressed to MAIL STOP SEQUENCE, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on

May 9, 2003.

Daba Conger 5/9/03
(Signature and Date)

RESPONSE TO CORRECTED NOTICE

COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

Dear Sir:

These papers are filed with the United States Patent and Trademark (USPTO) in response to a Notice the USPTO issued on January 24, 2003 in the above-identified Application. In the Notice, the USPTO withdrew its Notice of November 9, 2000 asserting it was sent in error, and issued a new Notice of Defective Response requiring the submission of the following:

- A paper copy of the Sequence Listing;
- The sequence listing in Computer Readable Form (CRF); and
- An amendment directing its entry into the Specification.

In response to this Notice, Applicants submit:

1. A paper copy of the sequence listing with Checker report showing no error and no warnings;
2. a diskette containing a CRF of the Sequence Listing;
3. a preliminary amendment that directs entry of the Sequence Listing into the instant Specification;
4. a Statement under 37 C.F.R. § 1.821;
5. A copy of the January 24, 2003 Notice; and
6. A petition for a three (3) month extension to reply, to and including May 24, 2003.

Fees

Authorization is hereby given to charge Deposit Account no. 18-1982 for any underpayment, or to credit any overpayments necessitated by the instant Submission.

Respectfully submitted,



William C. Coppola
Registration No. 41,686

AVENTIS PHARMACEUTICALS INC.
Route 202-206; Mail Stop: D-303A
P.O. Box 6800
Bridgewater, NJ 08807
Aventis Docket No.: ST98008A



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20231
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/646,399	Carole Ciolina	ST98008A

5487

ROSS J. OEHLER
 AVENTIS PHARMACEUTICALS INC.
 ROUTE 202 -206
 MAIL CODE: D303A
 BRIDGEWATER, NJ 08807

INTERNATIONAL APPLICATION NO.

PCT/FR99/00643

I.A. FILING DATE

03/19/1999

PRIORITY DATE

03/24/1998

CONFIRMATION NO. 8666

371 FORMALITIES LETTER



OC00000009408729

Date Mailed: 01/24/2003

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Claims
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Drawings
- Information Disclosure Statements
- Initial Application Filing Fees
- Oath or Declaration
- Oath or Declaration
- Original Specification
- Preliminary Amendments
- Request for Immediate Examination

Applicant's response filed 11/01/2000 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 10/23/2000 have not been completed.

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for a disclosure as set forth in 37 CFR 1.821 -1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked -up copy of the "Raw Sequence Listing."
 - The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
 - APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821 -1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308 -4216
 - To Purchase Patentln Software, call (703) 306 -2600
 - For Patentln Software Program Help, call (703) 306 -4119 or e -mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

LAMONT M HUNTER

Telephone: (703) 305-3686

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/646,399	PCT/FR99/00643	ST98008A